INTRODUCTION
============

Erectile dysfunction is a common complication after radical prostatectomy. With detailed understanding of the anatomy of the cavernous nerves \[[@B1]\], nerve-sparing procedures have been developed \[[@B2]\] and applied to carefully selected patients. Nevertheless, considerable numbers of patients who undergo radical prostatectomy become impotent. In one study, among men who were potent at baseline, the proportion who were impotent 18 or more months after surgery was 65.6% of men undergoing non-nerve-sparing procedures, 58.6% of men undergoing unilateral nerve-sparing procedures, and 56.0% of men undergoing bilateral nerve-sparing procedures \[[@B3]\]. Recovery of erectile dysfunction is slow, usually taking months to years, and even if the nerve-sparing procedure is done by experienced hands, one third of patients need the aid of medications such as phosphodiesterase inhibitors \[[@B4]\].

Cell transplantation and tissue engineering is an emerging field of science. In the field of urology, attempts have been made to engineer urological tissues, including the urethra \[[@B5]\], bladder \[[@B6],[@B7]\], and ureter \[[@B8]\]. These studies used autologous organ-specific cells to regenerate corresponding organs, but the use of such cells required a lot of time and material for cell proliferation; also, such cells could not be used in malignant conditions \[[@B9]\]. For these reasons, stem cells have emerged as the current trend in the study of cell transplantation and tissue engineering during the past decade. Muscle-derived stem cells (MDSCs) are adult stem cells located in muscles that are known to not only proliferate into muscle cells but also differentiate into various other tissues such as bone, cartilage, and fat \[[@B10]\]. Previously, umbilical cord blood mesenchymal stem cells were used in a rat model of cavernous nerve injury and showed improved erectile function \[[@B11]\]. In this study, we transplanted MDSCs in a rat model of cavernous nerve injury to study the effect on erectile function and also looked at the survival rate of MDSCs through immunohistochemical staining.

MATERIALS AND METHODS
=====================

1. Experimental animals
-----------------------

The Institutional Animal Care and Use Committee of the School of Medicine, the Catholic University of Korea, approved the experimental protocol. Sixteen-week-old adult white rats (Saemtaco Bio Inc., Osan, Korea) weighing about 300 to 350 g were used. Experimental groups were divided into 3: a control group (n=5, group I), a bilateral cavernous nerve injury group (n=5, group II), and a bilateral cavernous nerve injury group with MDSC injection (1×10^6^ cells in 20 µl; n=5, group III).

2. Purification and proliferation of MDSCs
------------------------------------------

MDSCs were harvested from the femoral muscles of white rats by use of a modified preplate technique as previously described \[[@B12],[@B13]\]. First, muscle tissue was extracted from the femoral muscle of the white rat and was minced into a coarse slurry with razor blades. Cells were enzymatically dissociated by the addition of collagenase-type XI 0.2% for 1 hour at 37.1℃, dispase (grade II 240 unit) for 45 minutes, and trypsin 0.1% for 30 minutes. The dissociated cells were preplated on a collagen-coated flask for 1 hour and this flask was termed pp1. The nonadhering cells were then transferred to another collagen-coated flask for 2 hours to obtain pp2 and this procedure was repeated at 24-hour intervals until pp4. The pp4 population was used for this experiment. The proliferation medium was Dulbecco\'s modified Eagle\'s medium with 10% fetal bovine serum, 10% horse serum, 0.5% chick embryo extract, and 1% penicillin/streptomycin. Proliferation was done for 4 days. All culture media and other supplies were purchased from Gibco Laboratories (Grand Island, NY, USA).

3. Cavernous nerve transection and transplantation of MDSCs
-----------------------------------------------------------

Tiletamine 0.2 ml was administered intraperitoneally for anesthesia. A low-midline abdominal incision was made, exposing the bladder and prostate. The pelvic ganglion was identified at the area lateral to the prostate on both sides. From the pelvic ganglion, cavernous nerves were identified to travel post-laterally into the corpus cavernosum. Group I rats were closed without nerve injury. In group II rats, the cavernous nerves were transected 2 to 3 mm distal to the pelvic ganglion and the wound was sutured. In group III rats, the cavernous nerves were transected and MDSCs (1×10^6^ cells in 20 µl) labeled with PKH-26 fluorescent cell linker (Sigma, St. Louis, MO, USA) were injected into the corpus cavernosum and the wound was then sutured.

4. Measurement of peak intracavernosal pressure and drop rate
-------------------------------------------------------------

After 4 weeks, peak intracavernosal pressure (ICP) and the drop rate were measured for all rats. Tiletamine 0.2 ml was administered intraperitoneally for anesthesia. A low-midline abdominal incision was made and the pelvic ganglion and cavernous nerve were exposed on both sides. The penis was also opened and the corpus cavernosum was exposed. A 23 G needle connected to a polyethylene tube was inserted into the corpus cavernosum to measure peak ICP and the drop rate. Papaverine (5 mg/kg) was injected into the corpus cavernosum to induce erection.

5. Histology
------------

After measurement of peak ICP and the drop rate, the penises were removed and the rats were sacrificed with intravenous sodium pentobarbital (100 mg/kg). The tissue specimens were fixed in 4% paraformaldehyde solution at 4℃ for one day. The next day, the specimens were serially transferred into 10%, 20%, and 30% sucrose that was dissolved in 0.1 M phosphate buffer (PB), and at each stage, they were left to sink down completely. They were then embedded in optimal cutting temperature (OCT) compound (Tissue-Tek, Miles Laboratory, Elkhart, IN, USA) in liquid nitrogen at -80℃ and sectioned at 10 µm on a cryostat (Microm, Walldorf, Germany). Sections were mounted on gelatin-coated slides and the slides were stained for hematoxylin and eosin. To identify PKH-26-labeled MDSCs, DAPI staining was done to group III and the cells were observed under a fluorescent microscope.

6. Analysis of cyclic guanosine monophosphate
---------------------------------------------

Measurement of the cyclic guanosine monophosphate (cGMP) level was performed by the use of a commercially available radioimmunoassay kit, the cGMP \[^125^I\] assay kit (Amersham International, Amersham, UK). The principles of the current experiment were to induce competitive bonding between ^125^I-labeled cGMP, which is present at a certain amount in the cells, and intracellular cGMP, to measure the amount of isotopes of ^125^I-labeled cGMP, and thereby to quantify the level of cGMP that is present in the sample. Following the preliminary experiment, the level of cGMP was lower in the cells and tissue forming the corpus cavernosum. An analysis was therefore performed by using an acetylation assay. Dried cytoplasmic extracts were dissolved by using assay buffer contained in a kit, to which acetylation reagent, antiserum, and \[^125^I\]cGMP were added in a sequential manner. Following this, the reaction was performed in compliance with the kit protocol. Eventually, with the use of a gamma scintillation counter, the radioactivity (cpm/min) of each tube was measured. The level of cGMP of each sample was calculated by use of a standard curve.

7. Statistical analysis
-----------------------

All data are presented as means±standard deviations, and p-values\<0.05 are reported as significant. Comparisons between groups were performed by using Sigmastat for Windows (Systat Inc., Chicago, IL, USA). The Mann-Whitney test was used to compare results.

RESULTS
=======

1. Change in erectile function
------------------------------

At 4 weeks, after papaverine injection to induce erection, the peak ICP of group I (control group) was 120±12.8 mmHg, that of group II (bilateral cavernous nerve injury group) was 52±8.7 mmHg, and that of group III \[bilateral cavernous nerve injury group with MDSCs (1×10^6^ cells in 20 ml) injection\] was 97±15.6 mmHg. The drop rate of group I was 10±4.1 mmHg/min, that of group II was 34±6.5 mmHg/min, and that of group III was 17±4.9 mmHg/min. The peak ICP and drop rate were significantly higher in group III than in group II (p\<0.05) ([Fig. 1](#F1){ref-type="fig"}).

2. Survival of MDSCs
--------------------

PHK-26 labeled MDSCs were identified by DAPI staining of the cavernosum of group III rats ([Fig. 2](#F2){ref-type="fig"}).

3. Expression of cGMP
---------------------

The expression of cGMP was significantly lower in group II (21.9±5.8 fmol/well) than in group I and group III (70.2±10.3 and 58.9±10.5 fmol/well, respectively) ([Fig. 3](#F3){ref-type="fig"}).

DISCUSSION
==========

Radical prostatectomy is the mainstay of treatment for localized prostate cancer. The number of prostatectomies performed in Korea is increasing as a result of prostate-specific antigen (PSA) screening and a younger age at diagnosis of prostate cancer \[[@B14]\]. Advances in surgical techniques and scientific technology have led to the advent of laparoscopic or robotic radical prostatectomy, but despite these developments, erectile dysfunction is still a major complication after radical prostatectomy and it compromises the quality of life of many patients undergoing this procedure \[[@B15],[@B16]\]. The primary cause of erectile dysfunction after radical prostatectomy is injury to the cavernous nerves. The injury leads to a decrease in elastic and smooth muscle fibers and a progressive increase in collagen fibers \[[@B17]\], resulting in fibrosis of the corpus cavernosum. Nerve-sparing procedures have been proven to be beneficial to sexual function after radical prostatectomy \[[@B18]-[@B20]\], but not all patients become potent and many patients depend on phosphodiesterase-5 inhibitors for satisfactory erection \[[@B4]\].

In this study, MDSCs were injected into a rat model of transected cavernous nerves to investigate the effect on erectile function after cavernous nerve injury. MDSCs are adult stem cells found in muscle tissues. They are free from the ethical problems frequently encountered in the use of embryonic stem cells \[[@B21]\], adequate amounts are easily obtained from autologous muscle biopsies in a short period of time, and they pose lower immunogenic and carcinogenic risks than do embryonic stem cells. These qualities make MDSCs a good material for recent studies involving cell transplantation and tissue engineering.

In this study, 4 weeks after injecting MDSCs into the corpus cavernosum of bilateral cavernous nerve injury rats, we observed a stable survival rate of MDSCs by immunostaining. In the functional study, the group with bilateral cavernous nerve injury with MDSCs injection showed improved erectile function, as peak ICP was significantly higher and the drop rate was lower compared with the bilateral cavernous nerve injury group. Also, the increased cGMP expression of group III suggested that MDSCs protected the penile nerve or muscle from atrophy after cavernous nerve transection. It is postulated that the MDSCs converted into muscle cells or neuronal cells, thereby reversing or preventing the fibrotic effect of the cavernous nerve transection seen in the bilateral cavernous nerve injury group. It is these muscle cells that are thought to be involved in improving the erectile function. In a similar study, Kim et al injected skeletal-muscle derived cells (MDCs) into the corpora cavernosa of bilateral cavernous nerve injury rats \[[@B22]\]. Maximal ICP was significantly higher in the MDC injection group than in the sham injection group. This study further demonstrated nerve fiber regeneration in the MDC injection group by staining for neuronal marker. The investigators postulated that either the MDCs protected the penile nerve from atrophy after cavernous nerve transection or the MDCs differentiated into a neuronal phenotype.

Growth factors may also have a role in improving erectile function after MDSC injection. There are several reports of improved erectile function after growth factor therapy. Chen et al reported an erectile recovery effect of brain-derived neurotrophic factor and vascular endothelial growth factor in a rat model of bilateral cavernous nerve injury, and Fandel et al reported similar results with intracavernosal growth differentiation factor-5 \[[@B23],[@B24]\]. These types of growth factors are thought to improve erectile function by regenerating injured nerve fibers. Stem cell injection may facilitate the activities of these growth factors. Bochinski et al showed improved erectile function in a rat model of cavernosal nerve injury after intracavernosally injecting embryonic stem cells that had differentiated along the neural cell line \[[@B25]\]. One of the mechanisms they postulated was that embryonic stem cells acted by producing growth factors.

One of the drawbacks of this study, as in other studies using MDSCs, is the need for a longer period of observation and ways to prolong the functional effect of MDSCs. Nolazco et al compared the stimulatory effect of MDSCs at week 2 and week 4 and showed that erectile function was higher at week 2, suggesting that new research is warranted to improve the survival of MDSCs and prolong the salutary functional effects for at least 3 to 6 months \[[@B26]\]. This means that a stable marker to detect donor cells for a long period would be required, rather than the short-lived fluorescent markers currently being used. Another drawback is that we need further study of the results of the differentiated cells from MDSCs in corpus cavernosum, even though we demonstrated improvement in erectile function.

Future studies in stem cell therapy would involve combination with other treatment modalities. Currently, phosphodiesterase-5 inhibitors are one of the main medical treatments of erectile dysfunction after radical prostatectomy. Combining stem cell therapy with medical therapy could produce a synergistic effect and warrants further study. In addition, combination with gene therapy is already producing promising results. Bivalacqua et al demonstrated improved age-related erectile dysfunction with the use of mesenchymal stem cells in which gene expression was modified by endothelial nitric oxide synthase \[[@B27]\]. Other applications of gene transfer in stem cell therapy may include transcription of growth factors for nerve regeneration or modifying the differentiation capacity of stem cells to the experimenters\' desire.

CONCLUSIONS
===========

MDSCs can improve erectile function in a cavernous nerve injury rat model. Erectile dysfunction resulting from radical prostatectomy may be treated with intracavernosal injection of MDSCs.
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